About Mark Welter

Before forming Oragen Technologies in 1996, Mark Welter served as vice president of research and  development at Ambico, Inc. in Dallas Center, Iowa for more than 20 years. In this capacity, he oversaw all virus, bacterial and parasitic research with a focus on the development of unique products for the international market.

 

Welter is widely know in the industry for his cutting-edge research aimed at preventing mucosal diseases. This research has resulted in numerous vaccines to help reduce infection in both pigs and cattle.

 

His major accomplishments include development of rotavirus vaccines, including the first USDA-licensed rotavirus vaccine for use in swine. This is the only modified live rotavirus vaccine for any animal containing more than one strain.

 

Welter has also developed 15 federally licensed vaccines for swine and cattle. His work has been published in 17 professional journals. And he has been awarded seven U.S. and three international patents.